开发和表征一个无载体干粉吸入器配方的清胺素的开发和表征
概括
这项研究开发了一种无载体干粉吸入器 (DPI) 配方,用于治疗肺炎. 优化的配方显示出增强的抗微生物活性和适合于无需辅助剂的肺部输送的特性.
科学领域:
- 制药科学 制药科学
- 药物输送系统 药物输送系统
- 肺部医学 肺部医学
背景情况:
- 针对肺部的药物输送系统中的辅助剂可能会引起副作用,并且适用性有限.
- 无载体系统提供了一个有希望的替代方案,以减轻肺部药物输送中的这些挑战.
研究的目的:
- 准备一种无载体干粉吸入器 (DPI) 配方的克拉里菌素用于肺炎治疗.
- 为了研究碳酸度对微粒子特性和空气动力学性能的影响.
- 为了评估开发的配方的疗效,与传统的克拉里思罗米相比.
主要方法:
- 克拉里思罗米辛微粒通过喷雾干燥甲醇:水溶液来制备.
- 碳酸被添加到不同度 (0.05%3.00%) 中以优化配方特性.
- 描述包括表面形态,粒子大小,泽塔潜力,热分析 (TGA,DSC),FT-IR,XRD,抗菌活性,空气动力学性能 (NGI),表面积和水分含量.
主要成果:
- 配方F9,含0.50%碳酸,表现为肺准的最佳特性,包括近乎球形,d50为4.76μm,MMAD为5.08μm.
- 描述证实了F9.的无形结构.
- 优化的配方显示,与未经处理的清菌素相比,抗微生物活性显著改善 (MIC和MBC较低).
结论:
- 通过喷雾干燥成功开发出一种有效的无载体DPI配方的克拉里胺.
- 优化的配方显示出卓越的抗菌疗效,为肺炎提供了有前途的局部治疗方法.
- 这种方法消除了对载体的需求,解决了与肺部药物输送中的传统辅助剂相关的局限性.
相关概念视频
01:23Inhaled Medications
923
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
923
01:30Asthma-IV: Diagnostic and Management
3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
209
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
209
01:23Oral Drug Delivery Systems: Introduction
104
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
104
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
275
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
275
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
389
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
389